Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Centre National Référent MESOPATH, Centre Leon Berard, Lyon, France.
Virchows Arch. 2021 Jan;478(1):59-72. doi: 10.1007/s00428-021-03031-7. Epub 2021 Jan 21.
The 2015 WHO classification of pleural mesotheliomas includes three major histologic subtypes-epithelioid, sarcomatoid, and biphasic. Recent genomic data has supported the need for a more granular and clinically valid classification beyond the three current subtypes. Because of tumor rarity and overlapping histologic features with other tumor types, diagnostic immunohistochemical work up is essential component in establishing the final diagnosis of mesothelioma. The use of BAP1 and CDKN2A/MTAP improves the diagnostic sensitivity of effusion specimens and are valuable in establishing the diagnosis of epithelioid mesothelioma. The major change in the forthcoming WHO classification is the inclusion of mesothelioma in situ as a diagnostic category. In this review, we discuss recently proposed changes in the histologic classification of pleural mesothelioma, differential diagnosis, and importance of ancillary diagnostic studies.
2015 年世界卫生组织(WHO)对胸膜间皮瘤的分类包括三种主要组织学亚型——上皮样、肉瘤样和双相型。最近的基因组数据支持在当前的三种亚型之外,需要进行更细致和更具临床意义的分类。由于肿瘤罕见且与其他肿瘤类型具有重叠的组织学特征,因此诊断免疫组织化学检查是确定间皮瘤最终诊断的重要组成部分。BAP1 和 CDKN2A/MTAP 的使用提高了胸腔积液标本的诊断敏感性,对于确定上皮样间皮瘤的诊断具有重要价值。即将发布的 WHO 分类中的主要变化是将原位间皮瘤纳入诊断类别。在这篇综述中,我们讨论了胸膜间皮瘤组织学分类的最新建议、鉴别诊断以及辅助诊断研究的重要性。